Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment

SM Proudman, WM Stevens, J Sahhar… - Internal medicine …, 2007 - Wiley Online Library
Pulmonary arterial hypertension (PAH) is an important cause of mortality in systemic sclerosis
(SSc). The symptoms are non‐specific and can be ascribed to other features of the disease…

[HTML][HTML] Role of autoantibodies in the diagnosis of connective-tissue disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF)

…, J Bleasel, GJ Keir, MA Nguyen, J Sahhar… - Journal of clinical …, 2017 - mdpi.com
The diagnosis of interstitial lung disease (ILD) requires meticulous evaluation for an underlying
connective tissue disease (CTD), with major implications for prognosis and management…

Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease–frontiers and horizons

AS Jee, J Sahhar, P Youssef, J Bleasel… - Pharmacology & …, 2019 - Elsevier
Disease behaviour in interstitial lung disease (ILD) is highly variable and accurate clinical
tools to predict prognosis and guide management decisions remain unsatisfactorily elusive. …

Early mortality in a multinational systemic sclerosis inception cohort

…, J Roddy, J Sahhar, W Stevens, J Walker… - Arthritis & …, 2017 - Wiley Online Library
Objective To determine mortality and causes of death in a multinational inception cohort of
subjects with systemic sclerosis (SSc). Methods We quantified mortality as standardized …

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease

…, V Thakkar, J Byron, J Sahhar, J Roddy… - …, 2013 - academic.oup.com
Objectives. In a multi-centre study, we sought to determine whether extent of disease on
high-resolution CT (HRCT) lung, reported using a simple grading system, is predictive of decline …

[HTML][HTML] Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian …

M Nikpour, P Hissaria, J Byron, J Sahhar… - Arthritis research & …, 2011 - Springer
Introduction The prevalence of antibodies to RNA polymerase III (anti-RNAP) differs among
systemic sclerosis (SSc) cohorts worldwide. Previously reported associations of anti-RNAP …

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)

…, S Pathare, S Proudman, A Rudin, J Sahhar… - Annals of the …, 2017 - ard.bmj.com
Objectives The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised
controlled trials very difficult. We aimed to use an observational approach to compare …

Interpretation of an extended autoantibody profile in a well‐characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis

…, J Zochling, J Sahhar, P Nash, J Roddy… - Arthritis & …, 2015 - Wiley Online Library
Objective To determine the relationships between systemic sclerosis (SSc)–related autoantibodies,
as well as their clinical associations, in a well‐characterized Australian patient cohort…

[HTML][HTML] A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis

…, J Roddy, J Walker, J Zochling, J Sahhar… - Arthritis research & …, 2015 - Springer
Introduction There is evidence that early screening for pulmonary arterial hypertension (PAH)
in systemic sclerosis (SSc) improves outcomes. We compared the predictive accuracy of …

[HTML][HTML] N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

…, P Hissaria, J Roddy, J Zochling, J Sahhar… - Arthritis research & …, 2012 - Springer
Introduction Pulmonary arterial hypertension is a major cause of mortality in systemic
sclerosis. N-terminal pro-brain natriuretic peptide (NT-proBNP) has emerged as a candidate …